Palabras clave
Azul de Toluidina
Displasia
Cómo citar
Resumen
Objetivos: evaluar el riesgo potencial maligno mediante la tinción de azul de toluidina y gradificación displásica de las lesiones verrucopapilares de la cavidad oral (LVPO).
Materiales y métodos: Se identificaron pacientes con LVPO localizados en la cavidad oral, se les aplicó azul de toluidina y posteriormente se evaluó los cambios displásicos para finalmente gradificarlos histopatológicamente en ausente, bajo o alto riesgo de transformación maligna. Pacientes que se negaron a la tinción con AT, no aceptaron la biopsia escisional o el tejido no poseía coilocitos, daño citopático asociado a la presencia del virus papiloma humano fueron eliminados del estudio.
Resultados: se incluyeron 34 pacientes con LVPO, 4 con tinción positiva al AT (3 fueron considerados intensos y 1 leve).
Conclusiones: las LVPO pueden emitir una tinción positiva al azul de toluidina así como presentar una variedad heterogenea de cambios displásicos arquitecturales y citológicos evaluados histopatologicamente, que en la totalidad de las muestras, de acuerdo al sistema binario, son clasificadas como riesgo leve de transformación maligna.
Referencias
Raff AB, Woodham A, Raff LM, Skeate J, Yan l, Da Silva DM, Schelhaas M, Kast M. The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol 2013;87(11):6062–6072.
Horvath CA, Boulet GA, Renoux VM, Delvenne PO, Bogers JP. Mechanisms of cell entry by human papillomaviruses: an overview. Virol J. 2010 Jan 20;7:11. doi: 10.1186/1743-422X-7-11. PMID: 20089191; PMCID: PMC2823669.
Syrjänen S. Oral manifestations of human papillomavirus infections. Eur J Oral Sci 2018;126(1):49–66.
Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(1):2-23. doi: 10.1002/rmv.1822. PMID: 25752814; PMCID: PMC5024016.
Awadallah M, Idle M, Patel K, Kademani D. Management update of potentially premalignant oral epithelial lesions. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(6):628-636.
Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation, and oxidative stress in human carcinogenesis. Int J Cancer. 2007;121(11):2381-6.
https://doi.org/10.1002/ijc.23192
Meštrović T, Ljubin-Sternak S, Božičević I, Drenjančević D, Barać A, Kozina G, Neuberg M, Vraneš J. Human Papillomavirus (HPV) Prevalence, Temporal Dynamics and Association with Abnormal Cervical Cytology Findings in Women from Croatia: Is there a Compounding Effect of Low-Risk/High-Risk HPV Co-Infection? Clin Lab. 2020;66(12). doi: 10.7754/Clin.Lab.2020.200406. PMID: 33337847.
Roza, A.L.O.C, Fonsêca, T.C, Mariz, B.A.L.A. et al. Human Papillomavirus-Associated Oral Epithelial Dysplasia: Report of 5 Illustrative Cases from Latin America. Head and Neck Pathol 2023;17:921–93. doi: 10.1007/s12105-023-01589-z. Epub 2023 Oct 16. PMID: 37843735; PMCID: PMC10739682.
Woo SB, Robinson M, Thavaraj S HPV-associated oral epithelial dysplasia. In: WHO Classifcation of Tumours Editorial Board. Head and neck tumours. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 07 24]. (WHO classifcation of tumours series, 5th ed.; vol. 9). Available from: https://tumourclassifcation.iarc.who.int/chapters/52
Majchrzak, E, Szybiak, B, Wegner, A, Pienkowski, P, Pazdrowski, J., Luczewski, L., et al. Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature. Radiol Oncol 2014;48(1):1-10.
Llewellyn, C.D., Johnson, N.W., Warnakulasuriya, K.A. Risk factors for squamous cell carcinoma of the oral cavity 392 in young people-a comprehensive literature review. Oral Oncol, 2001;37(5):401-418.
Mills S. How effective is toluidine blue for screening and diagnosis of oral cancer and premalignant lesions? Evid Based Dent. 2022;23(1):34-35.
Yang EC, Tan MT, Schwarz RA, Richards-Kortum RR, Gillenwater AM, Vigneswaran N. Noninvasive diagnostic adjuncts for the evaluation of potentially premalignant oral epithelial lesions: current limitations and future directions. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(6):670-681.
Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79(3):321–329.
Sridharan G, Shankar AA. Toluidine blue: A review of its chemistry and clinical utility. J Oral Maxillofac Pathol. 2012;16(2):251-5.
Miller RL, Simms BW, Gould AR. Toluidine blue staining for detection of oral premalignant lesions and carcinomas. J Oral Pathol Med. 1988;17:73–8.
Yan F, Reddy PD, Nguyen SA, Chi AC, Neville BW, Day TA. Grading systems of oral cavity pre-malignancy: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2020 Nov;277(11):2967-2976. doi: 10.1007/s00405-020-06036-1. Epub 2020 May 23. PMID: 32447493.
Kujan O, Oliver RJ, Khattab A, Roberts SA, Thakker N, Sloan P. Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. Oral Oncol 2006;42(10):987–993
Barnes LEJ, Reichart P, Sidransky S (2005) World Health Organization Classification of Tumors, Pathology and Genetics, Head and Neck Tumors. International Agency for Research on Cancer Press, Lyon
Reibel JGN, Hille J et al. Oral potentially malignant disorders and oral epithelial dysplasia. In: El-Naggar AKCJ, Grandis JR, et al. (eds) WHO Classifcation of Head and Neck Tumours, 4th edn. International Agency for Research on Cancer, Lyon, pp 2017; 112–113.
Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 2008;87(1):14–32.
Epstein JB, Scully C, Spinelli J. Toluidine blue and Lugol's iodine application in the assessment of oral malignant disease and lesions at risk of malignancy. J Oral Pathol Med. 1992;21:160–3.
Gandalfo S, Pentenero M, Broccoletti R, Pagano M, Carrozzo M, Scully C. Toluidine blue uptake in potentially malignant lesions in vivo: Clinical and histological assessment. Oral Oncol. 2006;42:89–95.
Jayaraman S, Pazhani J, PriyaVeeraraghavan V, Raj AT, Somasundaram DB, Patil S. PCNA and Ki67: Prognostic proliferation markers for oral cancer. Oral Oncol. 2022 Jul;130:105943. doi: 10.1016/j.oraloncology.2022.105943. Epub 2022 May 30. PMID: 35653815.
Dixit R, Bhavsar C, Marfatia YS. Laboratory diagnosis of human papillomavirus virus infection in female genital tract. Indian J Sex Transm Dis AIDS. 2011 Jan;32(1):50-2. doi: 10.4103/0253-7184.81257. PMID: 21799579; PMCID: PMC3139291.
Gupta A, Singh M, Ibrahim R, Mehrotra R. Utility of toluidine blue staining and brush biopsy in precancerous and cancerous lesions. Acta Cytol 2007;51(5):788-94. doi: 10.1159/000325843. PMID: 17910350.
Snietura M, Lamch R, Kopec A, Waniczek D, Likus W, Lange D, Markowski J. Oral and oropharyngeal papillomas are not associated with high-risk human papillomavirus infection. Eur Arch Otorhinolaryngol. 2017;274(9):3477-3483.
Piemonte ED, Gilligan MG, Lazos JP, Panico RL. Tinción con azul de toluidina en biopsia dirigida de lesiones displásicas de la mucosa bucal. Informe de casos clínicos. Rev Asoc Odontol Arg. 2021;109(1):49-58.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2024 Jorge García Barragán, Rogelio González-González, Ronell Bologna-Molina, Victor Toral Rizo, Germán Villanueva Sánchez, Sandra López Verdín